A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Doravirine/islatravir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DOR/ISL Blinded Label Switch; ILLUMINATE SWITCH B
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 30 Mar 2025 Status changed from suspended to completed.
- 26 Jun 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 28 Feb 2024 Planned End Date changed from 31 May 2024 to 25 Feb 2025.